ScienceDaily: Lymphoma News

Channel Description:

Latest Articles in this Channel:

05/26/10--12:15: Promising treatment for aggressive lymphoma identified in new study (chan 1453797)

New research illustrates that some patients with transformed lymphoma showed "remarkable" response to lenalidomide, an oral drug with few side effects.


05/27/10--14:09: New explaination of how certain cancers develop (chan 1453797)

Researchers have discovered a new interaction between a cell signaling system and a specific gene that may be the cause of B-cell lymphoma. The finding suggests a similar interaction could be occurring during the development of other types of cancer, leading to further understanding of how cancer works -- and how it might be stopped.


06/07/10--11:20: 'Scout scans' map the way in non-Hodgkin's lymphoma treatment (chan 1453797)

According to a new study, molecular imaging can evaluate and optimize non-Hodgkin's lymphoma therapy with Zevalin, a front-line radioimmunotherapy drug that uses a dose of radioactive material and mimics the body's own immune response to target and kill cancer cells while sparing nearby healthy tissues.


06/07/10--12:13: New way found to attack cancerous cells (chan 1453797)

Scientists have discovered a new way to target and destroy a type of cancerous cell. The findings may lead to the development of new therapies to treat lymphomas, leukemias and related cancers.


06/14/10--14:18: Control of cancer cell pathways key to halting disease spread, study shows (chan 1453797)

Scientists have deciphered a part of the pathway used by a well-known oncogene called Myc to exert its malignant effect. Their findings confirm that at least some cancerous cells have within them the seeds to stop their own growth, if Myc can first be disabled.


06/19/10--06:59: Primary Sjogren's Syndrome: Blood deficiencies are strong predictors of poor outcome (chan 1453797)

For health care professionals diagnosing primary Sjogren's Syndrome (pSS, an autoimmune disorder in which immune cells attack and destroy moisture-producing glands), the incidence of blood based deficiencies is the strongest predictor of a poor outcome in patients, according to the results of a new study.


07/02/10--06:22: Lymphoma patients with cardiovascular disease have increased risk of cardiac hospitalization, study finds (chan 1453797)

Older patients with Hodgkin lymphoma (HL) and a history of heart disease face a high risk of hospitalization for cardiac complications after completing treatment, according to new research. HL is a form of cancer of arising in the lymph nodes, and approximately 8,500 people were diagnosed with the disease in 2009, according to the American Cancer Society.


07/06/10--12:06: Multicolor quantum dots aid in cancer biopsy diagnosis (chan 1453797)

The tunable fluorescent nanoparticles known as quantum dots make ideal tools for distinguishing and identifying rare cancer cells in tissue biopsies. Researchers have learned how multicolor quantum dots linked to antibodies can distinguish the Reed-Sternberg cells that are characteristic of Hodgkin's lymphoma.


07/12/10--09:18: Progress made in elucidating the mechanisms of bortezomib in lymphoma (chan 1453797)

A new study sheds light on how bortezomib, the first in a new class of cancer drugs known as proteasome inhibitors, works in mantle cell lymphoma. The study also provides preliminary evidence for which patients might benefit most from bortezomib. Additionally, researchers demonstrate that biomarkers -- the genes and proteins that indicate biological processes -- might help guide the selection of patients for specific clinical trials and speed-up the development of targeted cancer drugs.


07/28/10--09:09: New criteria for T-cell lymphoma diagnosis (chan 1453797)

Researchers in Italy have discovered new diagnostic criteria to differentiate peripheral T-cell lymphomas (PTCLs).


08/18/10--17:53: Targeting hit-and-run cancer viruses (chan 1453797)

Viruses that can invade host cells, initiate cancer and then flee from their own trail of destruction could be stopped in their tracks, say researchers.


09/01/10--07:37: Personalized medicine: Molecular imaging predicts treatment success in many cancers (chan 1453797)

New studies show that molecular imaging plays a critical role in the evaluation and treatment planning for a broad spectrum of cancers, including thyroid cancer and lymphoma.


09/07/10--10:15: New lymphoma treatment shows promise in dogs (chan 1453797)

Researchers have identified a new target for the treatment of lymphoma and are testing a potential new drug in pet dogs afflicted with the disease. At low doses, the compound, called S-PAC-1, arrested the growth of tumors in three of six dogs tested and induced partial remission in a fourth.


09/09/10--09:28: Improvement in prediction of blood clots in cancer patients (chan 1453797)

For cancer patients, who have an increased risk of developing venous thromboembolism due to a hyperactive blood coagulation system, there is now an enhanced risk model to predict their chance of developing blood clots, according to a recent study.


09/23/10--09:51: Cancer researchers discover new signaling pathway that controls cell development and cancer (chan 1453797)

Researchers have discovered a new cell signaling pathway that controls cell growth and development, a pathway that, when defective, helps promote the formation of several major forms of human cancer, including lymphoma and leukemia.


09/29/10--07:56: Hodgkin's lymphoma: Benefit of stem cell transplantation with an unrelated donor unclear (chan 1453797)

It remains an unresolved question whether adult patients with Hodgkin's lymphoma, a certain type of lymph node cancer, benefit from allogeneic stem cell transplantation with an unrelated donor, according to a new report.


10/19/10--08:15: SHIP protein identified as a B-cell tumor suppressor (chan 1453797)

Researchers discover how the enzyme SHIP regulates B-cell growth in mice, findings that could impact lymphoma drugs in development.


10/25/10--10:37: Newer, more intense chemotherapy with less radiation not more effective against Hodgkin's lymphoma, study finds (chan 1453797)

A lower dose of radiation used to reduce side effects is not as effective as the regular dose when given with the standard chemotherapy in the treatment of Hodgkin's lymphoma patients with early, intermediate-stage disease, according to a first-of-its-kind randomized study.


10/28/10--09:10: Cancer's hiding spots revealed (chan 1453797)

In a study of mice with lymphoma, biologists have discovered that a small number of cancer cells escape chemotherapy by hiding out in the thymus, an organ where immune cells mature. Within the thymus, the cancer cells are bathed in growth factors that protect them from the drugs' effects. Those cells are likely the source of relapsed tumors, said the lead researcher.


11/01/10--10:16: Lymphoma and leukemia discovery may improve therapy (chan 1453797)

Scientists have identified a mechanism regulating activation-induced deaminase, which could be important for the therapy of some types of lymphoma and leukemia.


11/03/10--14:14: Armed antibody triggers remissions for Hodgkin's lymphoma (chan 1453797)

An antibody loaded with an anti-cancer agent produced complete or partial remissions in 38 percent of patients with relapsed or therapy-resistant Hodgkin lymphoma enrolled in a phase I clinical trial, researchers report.


11/03/10--14:16: New lymphoma therapy may be more effective with fewer side effects (chan 1453797)

Diffuse large B-cell lymphoma is a type of aggressive non-Hodgkin's lymphoma that accounts for approximately 40 percent of lymphomas among adults. If left untreated, it is fatal. The existing treatments have a cure rate that is slightly over 50 percent but destroy healthy cells along with the cancer cells. Researchers have now found a combination therapy that is more effective than traditional treatments and is able to kill the cancer cells without harm to surrounding tissues.


11/09/10--15:32: Long-term statin use is unlikely to increase cancer risk, study finds (chan 1453797)

Researchers have further established that long-term use of statins is unlikely to substantially increase or decrease overall cancer risk, according to a new study.


12/06/10--07:12: New standards of care and novel treatment options for several forms of lymphoma unveiled (chan 1453797)

New research points to promising new options for the standard treatment of advanced asymptomatic follicular lymphoma, mantle cell lymphoma, and early, unfavorable Hodgkin disease. Other research highlights the efficacy of an innovative investigational agent that has the potential to become a new treatment option for patients with relapsed or refractory Hodgkin disease, which currently has no available treatment options.


12/06/10--13:17: Personalized vaccine for lymphoma patients extends disease-free survival by nearly 2 years (chan 1453797)

A personalized vaccine is a powerful therapy to prevent recurrence among certain follicular lymphoma patients, according to the latest results. When these patients -- whose tumors are marked by a specific protein that may be present in up to half of people with this type of cancer -- receive a vaccine made from their own tumor cells, disease-free survival is improved by nearly two years, compared with patients who receive a placebo.


12/06/10--17:12: Drug resistance of chronic lymphocytic leukemia in bone marrow and lymph nodes (chan 1453797)

Scientists now offer a new explanation of why chronic lymphocytic leukemia (CLL) tends to recur in the lymph nodes and bone marrow after being cleared from the bloodstream by chemotherapy.


12/07/10--06:18: Aggressive blood cancers: Adoptive transfer of treg-depleted donor Th1 and Th2 cells safely accelerates alloengraftment after low-intensity chemotherapy (chan 1453797)

Researchers conducted a clinical trial to evaluate the effectiveness of infusing cultured donor immune cells known as "T-rapa" cells after stem cell transplantation into patients being treated for blood-related cancers.


12/07/10--09:59: Aggressive blood cancers: Is Pralatrexate effective in patients with T-cell lymphoma who fail ICE-based regimens? (chan 1453797)

Researchers analyzed data from the phase II pivotal trial of pralatrexate (known as the PROPEL study) -- which led to the FDA approval of pralatrexate in September 2009. Forty percent of study patients treated with pralatrexate showed a partial or complete response. The authors concluded that the efficacy of this medication as a standalone treatment compared favorably to ICE-based regimens.


12/15/10--09:19: Epstein-Barr: Scientists decode secrets of a very common virus that can cause cancer (chan 1453797)

About 90 percent of people are infected at some time in their lives with Epstein-Barr virus (EBV), usually with no ill effects. But individuals with compromised immune systems, such as people with organ transplants or HIV infection, have a greater risk of cancer occurring because of this virus. Scientists have discovered a pathway that infected cells use to root out EBV infections, a finding that has implications for understanding the human response to cancer-causing viruses in general.


12/22/10--11:17: Many cancer cells found to have an 'eat me' signal (chan 1453797)

Researchers have discovered that many cancer cells carry the seeds of their own destruction -- a protein on the cell surface that signals circulating immune cells to engulf and digest them. On cancer cells, this "eat me" signal is counteracted by a separate "don't eat me" signal that was described in an earlier study.


01/27/11--11:17: How fusion protein triggers cancer (chan 1453797)

What happens when two proteins join together? In this case, they become like a power couple, where the whole is greater than the sum of the parts. The fusion protein API2-MALT1 joins with the enzyme NIK and cuts it in two, making NIK a renegade protein that fuels lymphoma.


01/31/11--12:35: Computer-assisted diagnosis tools to aid pathologists (chan 1453797)

Researchers are leveraging powerful Ohio Supercomputer Center resources to develop computer-assisted diagnosis tools for diagnosing Follicular Lymphoma. Accurate grading of the pathological samples generally leads to a promising prognosis, but diagnosis depends solely upon a labor-intensive process that can be affected by fatigue, reader variation and bias. These computer-assisted procedures will provide pathologists grading cancerous Follicular Lymphoma samples with quicker, more consistently accurate diagnoses.


01/31/11--13:13: Novel immune system-based gene therapy induces strong responses in metastatic melanoma, sarcoma (chan 1453797)

Researchers have found that a novel form of personalized therapy that genetically engineers a patient's own anti-tumor immune cells to fight tumors could treat metastatic melanoma and metastatic synovial cell sarcoma, representing a potentially new therapeutic approach against these and other cancers.


02/22/11--09:21: Cancer-causing virus exploits key cell-survival proteins (chan 1453797)

The human T-lymphotropic virus type 1, a cancer-causing retrovirus, exploits key proteins in host cells to extend the life of those cells, thereby prolonging its own survival and ability to spread, according to a new study. The virus, which causes adult T-cell leukemia and lymphoma, produces a protein called p30 that targets two important cell proteins, one involved in DNA damage repair, the other involved in the destruction of proteins within the cell.


03/07/11--06:30: Two proteins play key roles in Burkitt's lymphoma (chan 1453797)

A new study reveals new molecular insight into the understanding and treatment of Burkitt`s lymphoma, one of the most aggressive tumors affecting humans.


04/06/11--09:30: Sniffing out lymphoma by 'turning dogs into humans' (chan 1453797)

Researchers are narrowing the search for genes involved in non-Hodgkin's lymphoma -- by 'turning dogs into humans."


04/19/11--09:13: Link between breast implants and rare form of cancer confirmed, but cause remains unclear (chan 1453797)

Breast implants appear to be associated with a rare form of lymphoma, but there is not yet evidence to show that the cancer is caused by implants or to suggest an underlying mechanism for how the disease might develop, according to a new study.


05/31/11--13:21: Vaccine increases disease-free survival for follicular lymphoma patients: Study on personalized therapy may lead to a 'flood of new agents' (chan 1453797)

A lymphoma vaccine uniquely tailored for each patient extends disease-free survival by 14 months, with signs of an even better response for patients with a specific biological marker, scientists have reported.


06/06/11--06:27: Early transplants are no better than chemotherapy followed by transplant for non-Hodgkin lymphoma patients, study finds (chan 1453797)

Patients with a very aggressive form of non-Hodgkin lymphoma who receive a stem cell transplant after standard chemotherapy during their first remission have comparable survival rates to those who receive the same standard therapy alone and, if needed, a transplant when they relapse.


06/06/11--08:31: Survival niche for cancer cells (chan 1453797)

Cancer cells do not grow equally well everywhere in the body. Often, they first create the conditions in which they can grow. Immunologists and hematologists have now shown that specific forms of lymphoma also create their own survival niche.


06/08/11--16:51: B-cell lymphoma: New research provides breakthrough in understanding common cancer (chan 1453797)

Researchers have discovered valuable insight into how people develop B-cell lymphoma, one of the most common cancers. The team found that a mechanism different to that previously thought to be the cause of lymphoma may be responsible for the development of the disease.


07/14/11--16:14: Protein may help diagnose and treat lymphoma in people and dogs (chan 1453797)

A protein that appears to play a key role in the formation of lymphoma and other tumors by inhibiting a tumor-suppressing gene has been identified by a team of veterinary and human medicine researchers. The newly identified protein may be a potential target for diagnosing and treating lymphoma in humans and animals.


07/15/11--10:53: Lymphoma drug shrinks dog tumors, could lead to human treatment (chan 1453797)

There are many kinds of cancers of the immune system, but one, activated B-cell diffuse large B-cell lymphoma, is particularly common and pernicious. Researchers have now shown that dogs that develop this disease spontaneously share the same aberrant activation of a critical intracellular pathway with humans. They also found that a drug designed to disrupt this pathway helps kill tumor cells in the dogs' lymph nodes.


07/19/11--12:19: Possible drug targets for common non-Hodgkin's lymphoma discovered (chan 1453797)

Researchers have discovered a novel interaction between two proteins involved in regulating cell growth that could provide possible new drug targets for treating diffuse large B-cell lymphoma, the most common type of non-Hodgkin's lymphoma, according to a new study. The scientists report that they have found a complex relationship between ERK, a protein that helps to regulate cell survival, and CHK2, a protein involved in the cellular DNA damage response.


07/24/11--10:55: Two genetic variations predict second cancers after radiation for children with Hodgkin lymphoma (chan 1453797)

A genome-wide association study found two tiny genetic variations that predict which patients with Hodgkin's lymphoma are likely to develop radiation-induced second cancers years after treatment. This could help physicians reduce the risks for susceptible patients. Younger the patients and those who receive more radiation are most at risk. This late side effect is the second leading cause of death for Hodgkin's survivors.


07/25/11--10:26: Specialized regulatory T cell stifles antibody production centers: Discovery has potential implications for cancer, autoimmune disease (chan 1453797)

A regulatory T cell that expresses three specific genes shuts down the mass production of antibodies launched by the immune system to attack invaders, scientists have reported.


08/02/11--06:08: Disappearance of genetic material allows tumor cells to grow (chan 1453797)

Loss of a gene regulator is crucial for a rare type of skin cancer


08/04/11--09:46: Researchers find way to help donor adult blood stem cells overcome transplant rejection (chan 1453797)

Findings may suggest new strategies for successful donor adult stem cell transplants in patients with blood cancers such as leukemia, lymphoma and myeloma.


08/09/11--13:20: Study on silencing of tumor suppressor gene suggests new target for lymphoma (chan 1453797)

Researchers have found that a cancer-causing fusion protein works by silencing the tumor suppressor gene IL-2R common gamma-chain. The results suggest news targets for lymphoma and other types of cancer.


08/15/11--06:50: IMRT improves outcomes in patients with extranodal lymphoma of the head and neck, study suggests (chan 1453797)

Lymphoma is a cancer that affects organs of the immune system, including the lymph nodes. In a subtype of the disease called extranodal lymphoma, tumors arise in non-lymphoid organs, such as the tongue and tonsils. Patients with extranodal lymphoma of the head and neck often undergo radiation therapy, but this treatment frequently damages the salivary glands and causes dry mouth, which can lead to problems with eating, speaking and swallowing.


08/25/11--07:23: Greater impact of chemotherapy on fertility (chan 1453797)

Current estimates of the impact of chemotherapy on women's reproductive health are too low, according to a new study. The researchers say their analysis of the age-specific, long-term effects of chemotherapy provides new insights that will help patients and clinicians make more informed decisions about future reproductive options, such as egg harvesting.


09/07/11--16:23: Biological agents for rheumatoid arthritis associated with increased skin cancer risk, review finds (chan 1453797)

Biological agents used to treat rheumatoid arthritis seem to be associated with an increased risk of skin cancer, indicates a systematic review of published research.


10/18/11--12:52: Efficacy of non-Hodgkin's lymphoma vaccine demonstrated in dogs (chan 1453797)

An experimental vaccine is the first veterinary cancer vaccine of its kind that shows an increase in survival time for dogs with spontaneous non-Hodgkin's lymphoma. The work shows for the first time the feasibility and therapeutic efficacy of this alternative cell-based vaccine, which could be employed in the treatment of a number of different cancer types.


11/01/11--14:10: Recipients of organ transplants at increased risk for broad range of cancers, study finds (chan 1453797)

Patients who have received a solid organ transplant, such as kidney, liver, heart or lung, have an overall cancer risk that is double that of the general population, with an increased risk for many different types of malignancies, according to a new study.


11/02/11--13:12: Scientists outline steps toward Epstein-Barr virus vaccine (chan 1453797)

Epstein-Barr virus infects nine out of ten people worldwide at some point during their lifetimes. Infections in early childhood often cause no disease symptoms, but people infected during adolescence or young adulthood may develop infectious mononucleosis, a disease characterized by swollen lymph nodes, fever and severe fatigue.


12/12/11--09:46: Survival rates increase with chemotherapy alone in patients with limited-stage Hodgkin's lymphoma, study suggests (chan 1453797)

New research demonstrates that patients with limited stage Hodgkin's lymphoma have a better chance of long-term survival if they undergo a standard chemotherapy regimen as opposed to radiation-based treatment.


12/12/11--10:26: Study of two sisters sheds light on lymphoma evolution (chan 1453797)

A woman received a transplant from her sister to treat leukemia. Both sisters later developed lymphoma, suggesting transfer of a common ancestor. Finding gives scientists new insight into lymphoma development.


12/12/11--19:09: Researchers identify genetic mutation responsible for most cases of Waldenstrom's macroglobulinemia (chan 1453797)

Scientists have identified a gene mutation that underlies the vast majority of cases of Waldenstrom's macroglobulinemia, a rare form of lymphoma that has eluded all previous efforts to find a genetic cause.


01/25/12--07:19: A leukemia drug kills cancerous T-cells while sparing normal immunity, study suggests (chan 1453797)

Researchers report that low-dose Campath (alemtuzumab) not only treats patients with L-CTCL but does so without increasing their risk of infections.


02/17/12--11:56: A single protein helps the body keep watch over the Epstein-Barr virus (chan 1453797)

Some 90 percent of people are exposed to the Epstein Barr virus at some point in their life. Even though it is quickly cleared from the body, the virus can linger silently for years in small numbers of infected B cells. According to researchers, the immune system subdues the virus by watching for a single viral protein called LMP1.